CDISC significantly expanded its presence in Europe in 2011 and anticipates this trend will continue. CDISC has long had a presence in Europe through its European CDISC Coordinating Committee (E3C) founded in 2002, annual CDISC European Interchanges and partnerships with European organizations in the global healthcare and medical research industries.
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS).
Target Accrual: 256 patients
Study Coordinator:
Professor Philippe Maingon, the new Chair of the EORTC Radiation Oncology Group (ROG), sees the role of the group becoming more and more transversal, in direct connection with the disease oriented groups, and feels that this role will be reinforced in the future. New developments in the field of oncology, with the introduction of targeted therapy that should be tested in the preclinical setting, will be tested and favored in the future by the group.
The European Patients’ Academy on Therapeutic Innovation (EUPATI) project is a consortium of 29 organizations led by the European Patients' Forum and including the EORTC among others. EUPATI aims to provide scientifically reliable, objective, comprehensive information to patients on pharmaceutical research and development and increase the capacity of well-informed patients to be effective advocates and advisors, for example in clinical trials, with regulatory authorities and in ethics committees.
This educational opportunity has long been recognized as an opportunity for scientists, clinicians, and persons from other disciplines to learn the latest information about preventing cancer.
The summer program consists of two separate courses:
22-25 February 2012, Istanbul, Turkey
Dr. Yan Liu completed her medical studies at the Shanghai Jiaotong University College of Medicine in Shanghai, China, where she also received her Master of Medicine in Image Diagnosis. Following her medical studies she spent two years as a resident radiologist in the imaging diagnosis center at the Shanghai Children’s Medical Center.
Results of the EORTC 62072 PALETTE (PAzopanib ExpLorEd in SofT-Tissue Sarcoma) trial presented at the 2011 Annual Meeting of the American Society for Clinical Oncology demonstrated a statistically significant improvement in the time to first occurrence of tumour progression or death (progression free survival or PFS) for study patients treated with the multi-tyrosine kinase inhibitor pazopanib, compared to placebo. PALETTE is a randomised, double-blind, placebo controlled Phase III trial in patients with metastatic soft tissue sarcomas (excluding gastrointestinal stromal tumours and a
